您的位置:易推广 > 化工原料 > 化学试剂 > 分析试剂 > 武汉艾美捷科技有限公司 > 产品展示 > 生化试剂 > 附文献丨艾美捷InVivoPlus抗小鼠CTLA-4 (CD152)介绍

产品展示

附文献丨艾美捷InVivoPlus抗小鼠CTLA-4 (CD152)介绍

点击次数:0发布时间:2023/3/23 16:48:02

附文献丨艾美捷InVivoPlus抗小鼠CTLA-4 (CD152)介绍

更新日期:2023/3/23 16:48:02

所 在 地:中国大陆

产品型号:

简单介绍:9H10单克隆抗体与小鼠CTLA-4(细胞毒性T淋巴细胞抗原-4)反应,也称为CD152。CTLA-4是由Ctla33基因编码的4 kDa细胞表面受体,属于Ig超家族的CD28家族。

优质供应

详细内容

 The 9H10 monoclonal antibody reacts with mouse CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. CTLA-4 is a 33 kDa cell surface receptor encoded by the Ctla4 gene that belongs to the CD28 family of the Ig superfamily. CTLA-4 is expressed on activated T and B lymphocytes. CTLA-4 is structurally similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to the B7 family members B7-1 (CD80) and B7-2 (CD86). Upon ligand binding, CTLA-4 negatively regulates cell-mediated immune responses. CTLA-4 plays roles in induction and/or maintenance of immunological tolerance, thymocyte development, and regulation of protective immunity. The critical role of CTLA-4 in immune down-regulation has been demonstrated in CTLA-4 deficient mice, which succumb at 3-5 weeks of age due to the development of a lymphoproliferative disease. CTLA-4 is among a group of inhibitory receptors being explored as cancer treatment targets through immune checkpoint blockade. The 9H10 antibody has been shown to promote T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding.

 

9H10单克隆抗体与小鼠CTLA-4(细胞毒性T淋巴细胞抗原-4)反应,也称为CD152。CTLA-4是由Ctla33基因编码的4 kDa细胞表面受体,属于Ig超家族的CD28家族。CTLA-4在活化的T和B淋巴细胞上表达。CTLA-4在结构上与T细胞共刺激蛋白CD28相似,并且两种分子都与B7家族成员B7-1(CD80)和B7-2(CD86)结合。配体结合后,CTLA-4负调节细胞介导的免疫反应。CTLA-4在诱导和/或维持免疫耐受、胸腺细胞发育和保护性免疫调节中发挥作用。CTLA-4在免疫下调中的关键作用已在CTLA-4缺陷小鼠中得到证实,由于淋巴组织增生性疾病的发展,这些小鼠在3-5周龄时死亡。CTLA-4是一组通过免疫检查点阻断作为癌症治疗靶点的抑制受体。9H10抗体已被证明通过阻断CTLA-4与B7共受体的结合来促进T细胞共刺激,从而允许CD28结合。

21.png

艾美捷InVivoPlus抗小鼠CTLA-4 (CD152) #BP0131、#BP0032规格:

同种型 叙利亚仓鼠IgG

推荐的同种型对照 体内加多克隆叙利亚仓鼠 IgG

推荐的稀释缓冲液 体内纯 pH 7.0 稀释缓冲液

免疫原 小鼠CTLA-4-人IgG1融合蛋白

报告的应用程序 体内CTLA-4 体外中和 CTLA-4 中和

蛋白质印迹

配方 PBS,pH 7.0

不含稳定剂或防腐剂

内毒素* <1EU/mg (<0.001EU/μg)

通过LAL凝胶凝血测定法测定

集合体* <5%

由 DLS 确定

纯度 >95%

由 SDS-PAGE 决定

无 菌 0.2 μM 过滤

生产 从无动物设施中的组织培养上清液中纯化

纯化 蛋白 G

里德 AB_10950184

分子量 150 千达

小鼠病原体检测* 外切粒菌/鼠痘病毒: 阴性 汉坦病毒: 阴性 K 病毒: 阴性乳酸脱氢酶升高病毒: 阴性 淋巴细胞性脉络丛脑膜炎病毒: 阴性小鼠腺病毒: 阴性小鼠巨细胞病毒: 阴性小鼠肝炎病毒: 阴性小鼠分钟病毒: 阴性小鼠诺如病毒: 阴性小鼠细小病毒: 阴性

小鼠轮状病毒:肺支原体阴性:阴性 小鼠肺炎病毒:阴性 多瘤病毒:阴性呼肠孤病毒筛查:阴性 仙台病毒:阴性 泰勒鼠脑脊髓炎:阴性

存储 抗体溶液应以4°C的储备浓度储存。 不要冻结。

 

InVivoPlus抗小鼠CTLA-4 (CD152) 部分文献引用:

in vivo CTLA-4 neutralization

Hervieu, A., et al. (2013). "Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth" J Invest Dermatol 133(2): 499-508.

 

in vivo CTLA-4 neutralization

Goding, S. R., et al. (2013). "Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma" J Immunol 190(9): 4899-4909.

 

in vivo CTLA-4 neutralization

Waitz, R., et al. (2012). "Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy" Cancer Res 72(2): 430-439.

 

in vivo CTLA-4 neutralization

Balachandran, V. P., et al. (2011). "Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido" Nat Med 17(9): 1094-1100.

 

来源:https://www.amyjet.com/products/BXC-BP0131-5mg.shtml

联系我们

联系人:谭美

点击查看联系方式

企业档案

  • 会员类型:免费会员
  • 工商认证: 【已认证】
  • 最后认证时间:
  • 法人:
  • 注册号:
  • 企业类型:代理商
  • 注册资金:人民币万

script>
在线咨询

提交